The study by Gill et al1 suggested a higher risk of adverse outcomes including syncope, bradycardia, pacemaker insertions, and hip fractures in community-dwelling adults with dementia receiving cholinesterase inhibitors compared with well-matched controls. These findings have important implications, as the agents in question remain the mainstay of symptomatic treatment for an otherwise debilitating illness.
It is interesting to note that while the incidence of hospital visits for syncope are comparatively higher in the cholinesterase inhibitor cohort (2.2% vs 1.5% in controls, see Table 3 in Gill et al1), the incidences for all other adverse outcomes are actually almost identical between cholinesterase inhibitor and control groups (hospital visits for bradycardia, 0.5% vs 0.4%; pacemaker insertions, 0.3% vs 0.3%; and hospitalizations for hip fractures, 1.6% vs 1.6%). The significant difference noted in the event rates and subsequent hazard ratios are therefore mainly influenced by the shorter follow-up periods reported for the cholinesterase inhibitor group (hospitalization due to hip fractures, mean follow-up times were 252 days and 302 days for the cholinesterase inhibitor and control cohorts, respectively.) Unfortunately, there was no clarification for this disparity in the article text.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 29
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.